Heart Tronics Inc (HRTT)

[TechKim]

Willie Gault Demonstrates Signalife's Fidelity 100 at American College of Cardiology Scientific Session on March 26, 2007

GREENVILLE, S.C., March 26, 2007 /PRNewswire-FirstCall via COMTEX/ -- Signalife, Inc. (Amex: SGN) features Willie Gault demonstrating it's latest technology in booth #2875 at the American College of Cardiology Scientific Sessions Monday, March 26, 2007.

Willie Gault, Chicago Bears Super Bowl Champion, returns to New Orleans, where in 1986 he played to win the Super Bowl 20 Championship. Gault is demonstrating the Signalife heart-monitoring device, invented by Dr. Budimir Drakulic. Dr. Drakulic's patented breakthrough technology provides a unique platform for biomedical signal acquisition, classification and evaluation for the treatment of cardiovascular diseases.

Willie Gault and other world class Hall of Fame athletes, believe this device will save the lives of athletes and others who die of sudden cardiac arrest in this country and around the world. Gault founded the 501 C 3 charity foundation "Athletes For Life" to provide Signalife (www.signalife.com) heart monitors to YMCA, Boys and Girls Clubs, underprivileged high schools and colleges across the country. Willie Gault will access corporate sponsorship and donations to reach his goal of reducing the prevalence of sudden cardiac death in children and adults who have not already been diagnosed with cardiovascular disease.

Gault quotes, "This device is the most important device invented to help prevent sudden heart attacks in people young and old alike. We all have been affected by this problem. On a personal note I have lost six friends over the last two years, so it has become my mission to assist in the fight against cardiovascular disease. I am excited about the possibility of saving lives!"

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.

SOURCE Signalife, Inc.



CONTACT: Kevin Kading, [phone], for Signalife, Inc.

URL: http://www.Signalife.com
http://www.prnewswire.com
www.prnewswire.com

Copyright (C) 2007 PR Newswire. All rights reserved